AMRN - Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership
2025-07-30 14:07:27 ET
More on Amarin
- Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
- Amarin Is A Sell Despite The Large Cash Balance
- Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript
- Amarin Q2 2025 Earnings Preview
- Amarin inks licensing deal with Recordati for lead drug Vazkepa